Auxilium Pharmaceuticals (NASDAQ: AUXL) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it compare to its peers? We will compare Auxilium Pharmaceuticals to similar businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Valuation and Earnings

This table compares Auxilium Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Auxilium Pharmaceuticals N/A N/A -11.15
Auxilium Pharmaceuticals Competitors $564.12 million $96.17 million 40.15

Auxilium Pharmaceuticals’ peers have higher revenue and earnings than Auxilium Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Auxilium Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxilium Pharmaceuticals 0 0 0 0 N/A
Auxilium Pharmaceuticals Competitors 137 800 1748 59 2.63

As a group, “Biopharmaceuticals” companies have a potential upside of 13.56%. Given Auxilium Pharmaceuticals’ peers higher probable upside, analysts clearly believe Auxilium Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Auxilium Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%
Auxilium Pharmaceuticals Competitors -13,602.79% -100.87% -25.29%

Insider & Institutional Ownership

43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Auxilium Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals’ peers have a beta of 1.03, meaning that their average stock price is 3% more volatile than the S&P 500.

Summary

Auxilium Pharmaceuticals peers beat Auxilium Pharmaceuticals on 5 of the 8 factors compared.

Auxilium Pharmaceuticals Company Profile

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.